Published in Gastroenterology on July 29, 2011
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2013) 1.20
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2012) 1.19
Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol (2013) 0.88
Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil (2012) 0.87
Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. Am J Physiol Gastrointest Liver Physiol (2013) 0.87
Oxytocin decreases colonic motility of cold water stressed rats via oxytocin receptors. World J Gastroenterol (2014) 0.84
Cyclic Vomiting Syndrome: A Functional Disorder. Pediatr Gastroenterol Hepatol Nutr (2015) 0.81
Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. Br J Pharmacol (2015) 0.80
Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLoS One (2013) 0.79
Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.78
Molecular basis of the irritable bowel syndrome. World J Gastroenterol (2014) 0.78
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol (2015) 0.78
Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. Front Pharmacol (2016) 0.78
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil (2016) 0.77
Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease. PLoS One (2013) 0.77
Endocannabinoids in the Gut. Cannabis Cannabinoid Res (2016) 0.77
Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients. Dig Dis Sci (2016) 0.76
[Efficacy, tolerability, and safety of cannabinoids in gastroenterology : A systematic review]. Schmerz (2016) 0.76
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. Pharmacology (2015) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 6.55
Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc (1990) 3.34
Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol (2005) 2.82
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.93
Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol (2001) 1.79
Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet (2004) 1.68
Adrenergic modulation of human colonic motor and sensory function. Am J Physiol (1997) 1.59
Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat (2000) 1.48
Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 1.41
Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol (2001) 1.28
Rectal tone, distensibility, and perception: reproducibility and response to different distensions. Am J Physiol (1998) 1.24
Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.23
Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol (2007) 1.14
Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.13
Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol (2003) 1.13
Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther (1989) 1.13
Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol (2007) 1.05
Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil (2006) 1.02
Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil (2006) 1.00
Rimonabant Sanofi-Synthélabo. Curr Opin Investig Drugs (2004) 0.99
Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain (2003) 0.98
Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. Am J Physiol Gastrointest Liver Physiol (2008) 0.97
A pilot study of motility and tone of the left colon in patients with diarrhea due to functional disorders and dysautonomia. Am J Gastroenterol (1997) 0.94
Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol (2006) 0.93
Comparison of mathematical methods for calculating colonic compliance in humans: power exponential, computer-based and manual linear interpolation models. Neurogastroenterol Motil (2007) 0.92
Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. Neuropharmacology (2005) 0.84
Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther (2008) 0.84
The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol Motil (2010) 0.82
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol (2004) 0.80
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
Chronic constipation. N Engl J Med (2003) 4.58
The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol (2007) 3.65
A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology (2005) 2.64
Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology (2004) 2.63
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology (2004) 2.48
Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol (2003) 2.47
Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology (2003) 2.35
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol (2006) 2.30
Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14
Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13
Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol (2007) 2.07
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology (2012) 1.93
Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.93
Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol (2008) 1.90
Drawing a blank in functional dyspepsia? Gastroenterology (2006) 1.89
Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86
Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc (2005) 1.86
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc (2004) 1.85
Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol (2005) 1.84
Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case-control study. Am J Gastroenterol (2012) 1.82
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80
The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology (2008) 1.77
Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics (2003) 1.76
A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol (2004) 1.75
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Effect of exercise treadmill testing and stress imaging on the triage of patients with chest pain: CHEER substudy. Mayo Clin Proc (2005) 1.69
Increasing incidence of celiac disease in a North American population. Am J Gastroenterol (2013) 1.69
A system model of oral glucose absorption: validation on gold standard data. IEEE Trans Biomed Eng (2006) 1.66
Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol (2003) 1.66
A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol (2005) 1.64
Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol (2007) 1.63
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol (2002) 1.58
Incidence of pelvic floor repair after hysterectomy: A population-based cohort study. Am J Obstet Gynecol (2007) 1.56
Endoscopic "no hole" full-thickness biopsy of the stomach to detect myenteric ganglia. Gastrointest Endosc (2008) 1.55
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Continuous 12-lead electrocardiographic monitoring in an emergency department chest pain unit: an assessment of potential clinical effect. Ann Emerg Med (2003) 1.54
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53
Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity (Silver Spring) (2009) 1.52
Symptoms and quality of life in community women with fecal incontinence. Clin Gastroenterol Hepatol (2006) 1.52
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol (2008) 1.52
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51
Factors that predict relief from upper abdominal pain after cholecystectomy. Clin Gastroenterol Hepatol (2011) 1.50
Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol (2012) 1.47
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes (2007) 1.47
A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol (2009) 1.47
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol (2011) 1.47
Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. J Pediatr (2005) 1.46